XTL Biopharmaceuticals (NASDAQ:XTLB) Shares Cross Below 200 Day Moving Average – Should You Sell?

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB)’s stock price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.67 and traded as low as $2.43. XTL Biopharmaceuticals shares last traded at $2.4550, with a volume of 1,829 shares traded.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of XTL Biopharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, XTL Biopharmaceuticals has a consensus rating of “Sell”.

XTL Biopharmaceuticals Price Performance

The firm’s 50 day moving average price is $2.77 and its 200 day moving average price is $2.67. The stock has a market capitalization of $5.38 million, a P/E ratio of -3.81 and a beta of 1.38.

XTL Biopharmaceuticals (NASDAQ:XTLB) last issued its quarterly earnings data on Tuesday, June 30th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter. The business had revenue of ($0.26) million for the quarter.

XTL Biopharmaceuticals Company Profile

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.